Type of information: Financing round
Company: Allogene Therapeutics (USA - CA)
Amount: $120 Million
Funding type: financing round
- Allogene Therapeutics is advancing its allogeneic CAR T cell portfolio, which includes rights to 16 preclinical CAR T cell therapy targets and U.S. rights to UCART19, an allogeneic CAR T cell therapy candidate that is being developed for the treatment of CD19-expressing hematological malignancies. In partnership with Servier, UCART19 is in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).
- • On September 6, 2018, Allogene Therapeutics announced it has completed a $120 million private financing of convertible notes. Participants in this financing were primarily first-time investors in Allogene. The financing was
led by Perceptive Advisors and included Deerfield Management Company, Fidelity Management and Research Company, Franklin Templeton Investments, Jennison Associates (on behalf of certain clients), Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., the University of California Office of the Chief Investment Officer, venBio Select Advisor, as well as additional large mutual funds.
Therapeutic area: Cancer - Oncology